New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
11. Dezember 2024 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has...
ADHD: What You Need to Know
19. November 2024 10:00 ET
|
Brain & Behavior Research Foundation
New York, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common mental health disorders of childhood. On Wednesday, December 4, 2024, at 7 p.m....
Annual International Conference on ADHD Hosted by CHADD, ADDA and ACO Provides Trusted Information, Guidance and Support to the ADHD Community
07. November 2024 08:00 ET
|
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
The Annual International Conference on ADHD 2024, hosted by CHADD, ADDA and ACO, will be held November 14 through 16 in Anaheim, California.
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
07. November 2024 07:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
29. Oktober 2024 07:48 ET
|
Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
October is ADHD Awareness Month
25. Oktober 2024 08:00 ET
|
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
October is ADHD Awareness Month, and CHADD is shining a spotlight on the critical importance of accurate diagnosis and effective treatment.
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
08. Oktober 2024 15:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...
Untapped Learning and Blue Sport Stable team up to sharpen athletes’ mental edge
01. Oktober 2024 08:00 ET
|
Untapped Learning
SUPERIOR, Colo., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Untapped Learning and Blue Sport Stable, home to the RoughRiders Sports Club, have partnered to provide comprehensive mental coaching services to...
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
12. September 2024 08:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in Benzinga All Live Access Event
27. August 2024 16:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...